Format

Send to

Choose Destination
Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17.

Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.

Author information

1
GSK, Rockville, MD, USA. Electronic address: martina.z.kovac@gsk.com.
2
GSK, King of Prussia, PA, USA. Electronic address: himallal@yahoo.com.
3
Westmead Institute for Medical Research, Westmead, NSW, Australia; University of Sydney, Sydney, NSW, Australia. Electronic address: tony.cunningham@sydney.edu.au.
4
Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: Myron.Levin@ucdenver.edu.
5
Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom. Electronic address: rwjbristol@doctors.org.uk.
6
GSK, Wavre, Belgium. Electronic address: laura.e.campora@gsk.com.
7
Università di Roma Tor Vergata, Rome, Italy. Electronic address: volpi@uniroma2.it.
8
GSK, King of Prussia, PA, USA. Electronic address: theineman@halozyme.com.

Abstract

BACKGROUND:

An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively).

METHODS:

Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.

RESULTS:

In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5-99.9%) in adults aged ≥50 years and 91.6% (43.3-99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.

CONCLUSIONS:

HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).

KEYWORDS:

Complications; Herpes zoster; Hospitalisation; Postherpetic neuralgia; Vaccine efficacy; Varicella-zoster virus

PMID:
29463421
DOI:
10.1016/j.vaccine.2018.02.029
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center